
Figure 1: Box plot, change in papilledema during the study
Variable | Value |
Sex, male n (%) | 2 (8) |
Age, years | 30. 6 (10.0) |
mean (SD) median (min; max) | 32.0 (10; 5) |
Treatment indication, n (%) | |
Refractory to medical therapy | 14 (56) |
Medication intolerance | 7 (28) |
Fulminant | 4 (16) |
BMI at enrollment, kg/m2 | |
Mean (SD) | 32.29 (5.12) |
Median (min; max) | 30.95 (22; 41) |
CSF opening pressure at diagnosis, mmHg | |
Mean (SD) | 357.08 (100.02) |
Median | 365 |
Pre-Stenting Meds, n (%) | |
ACTZ 1000 mg/d | 12 (48) |
ACTZ 2000 mg/d | 4 (16) |
ACTZ 3000 mg/d | 2 (8) |
ACTZ 1000 mg/bid +TPM 50mg/bid | 1 (4) |
ACTZ 1500 mg/d | 1 (4) |
ACTZ 2500 mg/d+ TPM 50 mg/d | 1 (4) |
ACTZ 500 mg/bid +TPM 50 mg/bid | 1 (4) |
ACTZ 2500 mg/d+ TPM 25 mg/d | 1 (4) |
TPM 100 mg/d | 1 (4) |
Post Stenting Meds, n (%) | |
None | 15 (60) |
ACTZ 500 mg/d | 5 (20) |
ACTZ 250 mg/d | 3 (12) |
ACTZ 750 mg/d | 1 (4) |
TPM 150 mg/d | 1 (4) |
Follow-up interval | ||||||
Variable | Pre-stent | First week | 1 month | 3 month | 6 month | 12 month |
OCT_RNFL, mean (SD) | 161 (93.3) | 165 (97.0) | 149 (35.9) | 88.5 (19.4) | 91.5 (16.4) | 83.5 (20.4) |
Median | 124 | 115 | 158 | 90 | 94 | 90 |
(min; max) | (50; 417) | (51; 348) | (99; 203) | (52; 129) | (55; 112) | (38; 111) |
Visual Fields, mean (SD) | -5.29 (6.58) | -4.16 (2.72) | -8.45 (10.07) | -3.69 (4.16) | -4.48 (7.62) | -3.92 (5.56) |
Median | -2.54 | -4.2 | -3.64 | -2.5 | -1.17 | -2.29 |
(min; max) | (-26.6; 0) | (-10.2; -0.1) | (-33.5 ;0) | (-15.5; 0) | (-29.7; 0.8) | (-20.4; 0) |
Visual acuity, mean (SD) | 0.26 (0.71) | 0.30 (0.33) | 0.21 (0.26) | 0.14 (0.10) | 0.12 (0.10) | 0.19 (0.19) |
Median | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
(min; max) | (0; 4.7) | (0; 1.3) | (0; 1.2) | (0; 0.4) | (0; 0.3) | (0; 1.0) |
Papilledema, mean (SD) | 2.21 (1.41) | 1.64 (1.28) | 1.27 (1.31) | 0.86 (0.94) | 0.23 (0.43) | 0.22 (0.56) |
Median | 2 | 1 | 1 | 1 | 0 | 0 |
(min; max) | (0; 5.0) | (0; 4.0) | (0; 3.0) | (0; 3.0) | (0; 1.0) | (0; 2.0) |
Variable | p-value | |
OCT-RNFL | -0.12 | <0.001 |
V/A | -0.02 | 0.17 |
Papilledema | -0.43 | <0.001 |
Visual Fields | ||
Right eye | 0.11 | 0.68 |
Left eye | 0.24 | 0.31 |
V/A- visual acuity
Table 3: Linear mixed effects model showing changes in clinical parameters over the 5 follow-up measurements
Figure 1: Box plot, change in papilledema during the study
Figure 2: Mean change in visual field 6 month after stenting
Tables at a glance
Figures at a glance